Drugs that contain Alendronate Sodium
1. Binosto patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7964212 | RADIUS | Effervescent compositions comprising phosphonates and methods related thereto |
Mar, 2023
(1 year, 1 month ago) | |
| US7488496 | RADIUS | Effervescent compositions comprising bisphosphonates and methods related thereto |
Aug, 2023
(8 months ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9592195 | RADIUS | Stable effervescent bisphosphonate formulations with rapid solubilization characteristics |
Dec, 2031
(7 years from now) | |
Market Authorisation Date: 12 March, 2012
Treatment: NA
Dosage: TABLET, EFFERVESCENT;ORAL
More Information on Dosage
BINOSTO family patents
2. Fosamax patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5681590 | ORGANON | Dry mix formulation for bisphosphonic acids |
Dec, 2012
(11 years ago) | |
| US6090410 | ORGANON | Dry mix formulation for bisphosphonic acids |
Dec, 2012
(11 years ago) | |
| US5358941 | ORGANON | Dry mix formulation for bisphosphonic acids with lactose |
Dec, 2012
(11 years ago) | |
| US6194004 | ORGANON | Dry mix formulation for bisphosphonic acids |
Dec, 2012
(11 years ago) | |
|
US5681590 (Pediatric) | ORGANON | Dry mix formulation for bisphosphonic acids |
Jun, 2013
(10 years ago) | |
|
US6090410 (Pediatric) | ORGANON | Dry mix formulation for bisphosphonic acids |
Jun, 2013
(10 years ago) | |
|
US5358941 (Pediatric) | ORGANON | Dry mix formulation for bisphosphonic acids with lactose |
Jun, 2013
(10 years ago) | |
|
US6194004 (Pediatric) | ORGANON | Dry mix formulation for bisphosphonic acids |
Jun, 2013
(10 years ago) | |
Market Authorisation Date: 25 April, 1997
Treatment: NA
Dosage: TABLET;ORAL
How can I launch a generic of FOSAMAX before it's drug patent expiration?
More Information on Dosage
FOSAMAX family patents
3. Fosamax patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5462932 | MERCK | Oral liquid alendronate formulations |
May, 2014
(9 years ago) | |
|
US5462932 (Pediatric) | MERCK | Oral liquid alendronate formulations |
Nov, 2014
(9 years ago) | |
| US6225294 | MERCK | Method for inhibiting bone resorption |
Jul, 2018
(5 years ago) | |
| US6015801 | MERCK | Method for inhibiting bone resorption |
Jul, 2018
(5 years ago) | |
| US5994329 | MERCK | Method for inhibiting bone resorption |
Jul, 2018
(5 years ago) | |
|
US6015801 (Pediatric) | MERCK | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) | |
|
US6225294 (Pediatric) | MERCK | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) | |
|
US5994329 (Pediatric) | MERCK | Method for inhibiting bone resorption |
Jan, 2019
(5 years ago) | |
Market Authorisation Date: 17 September, 2003
Treatment: NA
Dosage: SOLUTION;ORAL
How can I launch a generic of FOSAMAX before it's drug patent expiration?
More Information on Dosage
FOSAMAX family patents